Infinity Pharmaceuticals, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2014-11-06: Form 8-K; Period of report 2014-11-06; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2014-10-16: Form 8-K; Period of report 2014-10-16; Description 7.01 Regulation FD Disclosure; 8.01 Other Events; Details 7.01.
- 2014-09-26: Form 8-K; Period of report 2014-09-22; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2014-09-03: Form 8-K; Period of report 2014-09-02; Description 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2014-11-06 | 8-K | 2014-11-06 | 2.02 Results of Operations and Financial Condition | 2.02 On November 6, 2014, we issued a press release announcing our results for the quarter ended September 30, 2014 and will conduct a previously-announced, publicly-available conference call to discuss those results. | d818273d8k.htm |
| 2014-10-16 | 8-K | 2014-10-16 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 From time to time, we intend to conduct meetings with third parties in which our current corporate slide presentation is presented. 8.01 On October 16, 2014 we issued a press release announcing data from our Phase 2a study of duvelisib (IPI-145) in patients with mild, allergic asthma. | d806114d8k.htm |
| 2014-09-26 | 8-K | 2014-09-22 | 1.01 Entry into a Material Definitive Agreement | 1.01 On September 22, 2014, Infinity Pharmaceuticals, Inc. (the “Company”) entered into a First Amendment to Facility Agreement (the “First Amendment”) with affiliates of Deerfield Management Company, L.P. (the “Lenders”) to amend that certain Facility Agreement dated as of February 24, 2014 (the “Facility Agreement”) by and among the Company and the Lenders. | d795579d8k.htm |
| 2014-09-03 | 8-K | 2014-09-02 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On September 2, 2014, Infinity Pharmaceuticals, Inc. (“we”, “us” or “our”) entered into a collaboration and license agreement with AbbVie Inc., or AbbVie, which we refer to as the AbbVie agreement. 8.01 On September 3, 2014, we issued a press release announcing the entry into a collaboration and license agreement with AbbVie Inc. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d783588d8k.htm |
| 2014-08-05 | 8-K | 2014-08-05 | 2.02 Results of Operations and Financial Condition | 2.02 On August 5, 2014, we issued a press release announcing our results for the quarter ended June 30, 2014 and will conduct a previously-announced, publicly-available conference call to discuss those results. | d767248d8k.htm |
| 2014-08-04 | 8-K | 2014-07-29 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On July 29, 2014, we entered into an amendment to our agreement with Intellikine LLC, or Intellikine, and we refer to this amendment as the Intellikine Amendment. 8.01 We issued a press release on August 4, 2014, announcing the execution of an amendment to our agreement with Intellikine LLC. | d768492d8k.htm |
| 2014-06-19 | 8-K | 2014-06-17 | 5.07 Submission of Matters to a Vote of Security Holders | d744364d8k.htm | |
| 2014-05-06 | 8-K | 2014-05-06 | 2.02 Results of Operations and Financial Condition | 2.02 On May 6, 2014, we issued a press release announcing our results for the quarter ended March 31, 2014 and will conduct a previously-announced, publicly-available conference call to discuss those results. | d722649d8k.htm |
| 2014-03-10 | 8-K | 2014-03-06 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) On March 6, 2014, Martin Babler and Thomas J. Lynch, M.D. informed our company that they will retire from our Board of Directors (the “Board”) effective March 6, 2014. | d690697d8k.htm |
| 2014-02-25 | 8-K | 2014-02-24 | 1.01 Entry into a Material Definitive Agreement; 2.02 Results of Operations and Financial Condition; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 2.02 On February 25, 2014, the Company issued a press release announcing its results for the year ended December 31, 2013 and will conduct a previously-announced, publicly-available conference call to discuss those results. 2.03 The disclosure set forth above under Item 1.01 relating to the Facility Agreement and Guaranty is hereby incorporated by reference into this Item 2.03. 3.02 The Warrants described in Item 1.01 above were offered and sold in reliance upon exemptions from registration pursuant to Section 4(2) under the Securities Act. | d680866d8k.htm |
| 2014-02-10 | 8-K | 2014-02-07 | 5.04 Temporary Suspension of Trading Under Registrant's Employee Benefit Plans | 5.04 On February 7, 2014, Infinity Pharmaceuticals, Inc. (the “Company”) received the notice required by Section 101(i)(2)(E) of the Employment Retirement Income Security Act of 1974, as amended, and on February 10, 2014 provided a notice to the Company’s directors and executive officers informing them of a blackout period for the Infinity Pharmaceuticals, Inc. 401(k) Plan and Trust (the “Plan”). | d674485d8k.htm |
| 2014-02-04 | 8-K | 2014-01-31 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 (b) On January 31, 2014, Infinity Pharmaceuticals, Inc. (the “Company”) and Pedro D. Santabarbara, M.D., Ph.D., Chief Medical Officer, agreed that his employment with the Company will terminate effective February 14, 2014. 8.01 On February 4, 2014, the Company issued a press release announcing the promotion of David A. Roth, M.D. to Chief Medical Officer. | d669464d8k.htm |
| 2014-01-13 | 8-K | 2014-01-13 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 8.01 Other Events | 2.02 Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2013, the Company announced on January 13, 2014, that it expects to report that it had approximately $214 million in cash, cash equivalents and available-for-sale securities as of December 31, 2013. 7.01 From time to time, the Company intends to conduct meetings with third parties in which its current corporate slide presentation is presented. 8.01 On January 13, 2014, the Company issued a press release announcing its 2014 business goals and financial guidance. | d658773d8k.htm |